Popular culture tells us that many women lose interest in sex during or after menopausal transition, but those ageist and sexist messages aren’t supported by good scientific research. We want you to have the facts and offer a few helpful remedies.
Read More
Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.
Read More
Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.
Read More
FOR IMMEDIATE RELEASE Contact: Evita Almassi, [email protected]
or (202) 682-6240
Read More
Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
Read More
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder
Read More